Exciting Research Advancements in Pulmonary Hypertension
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical leader dedicated to developing innovative therapies for rare cardiopulmonary diseases, has announced a significant presence at the upcoming Pulmonary Hypertension Professional Association (PHPN) Symposium. This prestigious event will take place from September 18 to September 20, where Liquidia plans to showcase four important posters highlighting their latest research efforts.
Live Thematic Poster Presentations
During a live thematic poster session, Liquidia intends to share groundbreaking safety and exploratory efficacy data from their ASCENT study involving LIQ861 (now known as YUTREPIA™). The presentation will particularly focus on the outcomes for patients experiencing pulmonary hypertension associated with interstitial lung disease (PH-ILD) through Week 8 of the study.
Insights from the ASCENT Study
Liquidia's ASCENT study emphasizes the importance of thorough safety checks and exploratory efficacy data. YUTREPIA™ is designed to address the challenges faced by PH-ILD patients, and this session aims to provide invaluable insights from participant responses. These findings are integral to understanding how YUTREPIA™ can enhance patient care and treatment outcomes.
Prior Research Highlights
In addition to the new data, three previously published posters will also be presented. These posters delve into YUTREPIA’s positive impact on cardiac effort, the overall quality of life for patients, and insights into patient device use. Each of these topics is critical in showcasing the comprehensive benefits of this innovative treatment option.
Discussion Sessions at the Symposium
The posters will be shared during dedicated sessions on September 19, providing an opportunity for in-depth discussions among peers in the field. Here are the details for the presentations:
- Poster Session: Poster Board #1037
Abstract: A Continued ASCENT to Week 8: Initial Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients - Poster Session: Poster Board #1041
Abstract: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from the ASCENT Trial - Poster Session: Poster Board #1051
Abstract: Quality of Life (QOL) in PAH Patients Receiving an Inhaled Dry Powder Treprostinil (LIQ861) in the INSPIRE Study - Poster Session: Poster Board #1053
Abstract: Robustness of LIQ861, a Dry-Powder Inhaled Formulation of Treprostinil, in Patient Misuse Scenarios
Understanding YUTREPIA™
YUTREPIA is a groundbreaking inhaled dry-powder formulation of treprostinil. It's delivered through an easy-to-use, compact device that requires minimal effort. The drug is specifically indicated for treating pulmonary arterial hypertension (PAH) and PH-ILD, aiming to enhance exercise capabilities for those affected.
Innovative Technology Behind YUTREPIA™
Liquidia utilizes its proprietary PRINT technology to create uniform drug particles, which ensures effective deposition in the lungs for maximal therapeutic benefit. This innovative approach not only improves patient outcomes but transforms how treatments for pulmonary hypertension are delivered.
About Liquidia Corporation
Liquidia Corporation is committed to developing innovative therapies aimed at improving the quality of life for patients suffering from rare cardiopulmonary conditions. Their ongoing projects include the commercialization of YUTREPIA™ and the development of L606, an investigational sustained-release formulation of treprostinil, which is expected to offer benefits with a convenient dosage regimen. Currently, Liquidia also markets a generic Treprostinil Injection, continuing to expand its portfolio to better serve the needs of patients with pulmonary hypertension.
Frequently Asked Questions
1. What is YUTREPIA™?
YUTREPIA™ is an inhaled dry-powder formulation of treprostinil designed for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
2. When will Liquidia present its research?
Liquidia will present its research at the PHPN Symposium on September 19, during a thematic poster session.
3. How does YUTREPIA™ improve patient's quality of life?
YUTREPIA™ is designed to enhance exercise capability and reduce symptoms associated with pulmonary hypertension, thereby improving overall quality of life for patients.
4. What technology does Liquidia use for drug formulation?
Liquidia employs its PRINT technology to create precise and uniform particles for effective drug delivery to the lungs.
5. Who can I contact for more information about Liquidia?
For investor inquiries, reach out to Jason Adair at 919.328.4350 or jason.adair@liquidia.com. For media inquiries, contact Patrick Wallace at 919.328.4383 or patrick.wallace@liquidia.com.
